This Article Full Text Full Text (PDF) All Versions of this Article: 40/2/124    most recent 01.HYP.0000025904.23047.27v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mihailidou, A. S. Articles by Raison, M. Search for Related Content PubMed PubMed Citation Articles by Mihailidou, A. S. Articles by Raison, M. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB LOSARTAN POTASSIUM MAGNESIUM COMPOUNDS MAGNESIUM, ELEMENTAL POTASSIUM SODIUM SPIRONOLACTONE Related Collections Hypertension - basic studies

(Hypertension. 2002;40:124.)
© 2002 American Heart Association, Inc.

Scientific Contributions

Mineralocorticoid and Angiotensin Receptor Antagonism During Hyperaldosteronemia

Anastasia S. Mihailidou; Mahidi Mardini; John W. Funder; Matthew Raison

From the Department of Cardiology, Royal North Shore Hospital (A.S.M., M.M., M.R.), Sydney, Australia; The University of Sydney (A.S.M., M.M.), Sydney, Australia; and Baker Medical Research Institute (J.W.F.), Melbourne, Australia.

Correspondence to Dr Anastasia Susie Mihailidou, Department of Cardiology, Royal North Shore Hospital, Pacific Highway, St. Leonards, Sydney, NSW, Australia 2065. E-mail amihaili{at}doh.health.nsw.gov.au

Elevated aldosterone levels induce a spironolactone-inhibitable decrease in cardiac sarcolemmal Na⁺-K⁺ pump function. Because pump inhibition has been shown to contribute to myocyte hypertrophy, restoration of Na⁺-K⁺ pump function may represent a possible mechanism for the cardioprotective action of mineralocorticoid receptor (MR) blockade. The present study examines whether treatment with the angiotensin type 1 receptor antagonist losartan, with either spironolactone or eplerenone, has additive effects on sarcolemmal Na⁺-K⁺ pump activity in hyperaldosteronemia. New Zealand White rabbits were divided into 7 different groups: controls, aldosterone alone, aldosterone plus spironolactone, aldosterone plus eplerenone, aldosterone plus losartan, aldosterone plus losartan and spironolactone, and aldosterone plus losartan and eplerenone. After 7 days, myocytes were isolated by enzymatic digestion. Electrogenic Na⁺-K⁺ pump current (I_p), arising from the 3:2 Na⁺:K⁺ exchange ratio, was measured by the whole-cell patch clamp technique. Elevated aldosterone levels lowered I_p; treatment with losartan reversed aldosterone-induced reduced pump function, as did MR blockade. Coadministration of spironolactone or eplerenone with losartan enhanced the losartan effect on pump function to a level similar to that measured in rabbits given losartan alone in the absence of hyperaldosteronemia. In conclusion, hyperaldosteronemia induces a decrease in I_p at near physiological levels of intracellular Na⁺ concentration. Treatment with losartan reverses this aldosterone-induced decrease in pump function, and coadministration with MR antagonists produces an additive effect on pump function, consistent with a beneficial effect of MR blockade in patients with hypertension and congestive heart failure treated with angiotensin type 1 receptor antagonists.

Key Words: aldosterone • ion transport • hypertrophy • sodium-potassium pump • myocytes • rabbits

This article has been cited by other articles:

				A. Lymperopoulos, G. Rengo, C. Zincarelli, J. Kim, S. Soltys, and W. J. Koch An adrenal {beta}-arrestin 1-mediated signaling pathway underlies angiotensin II-induced aldosterone production in vitro and in vivo PNAS, April 7, 2009; 106(14): 5825 - 5830. [Abstract] [Full Text] [PDF]

				T. Imanishi, H. Ikejima, H. Tsujioka, A. Kuroi, K. Kobayashi, Y. Muragaki, S. Mochizuki, M. Goto, K. Yoshida, and T. Akasaka Addition of Eplerenone to an Angiotensin-Converting Enzyme Inhibitor Effectively Improves Nitric Oxide Bioavailability Hypertension, March 1, 2008; 51(3): 734 - 741. [Abstract] [Full Text] [PDF]

				J. W. Funder The Nongenomic Actions of Aldosterone Endocr. Rev., May 1, 2005; 26(3): 313 - 321. [Abstract] [Full Text] [PDF]

				R. B. de Paula, A. A. da Silva, and J. E. Hall Aldosterone Antagonism Attenuates Obesity-Induced Hypertension and Glomerular Hyperfiltration Hypertension, January 1, 2004; 43(1): 41 - 47. [Abstract] [Full Text] [PDF]

				S. I. McFarlane and J. R. Sowers Aldosterone Function in Diabetes Mellitus: Effects on Cardiovascular and Renal Disease J. Clin. Endocrinol. Metab., February 1, 2003; 88(2): 516 - 523. [Full Text] [PDF]